BioCryst Pharmaceuticals Receives Consensus Rating of “Buy” from Analysts (NASDAQ:BCRX)
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) have been given a consensus recommendation of “Buy” by the nine ratings firms that are covering the company, American Banking News.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.20.
A number of research firms have recently commented on BCRX. Analysts at Piper Jaffray initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday. They set an “overweight” rating and a $17.00 price target on the stock. Separately, analysts at Mizuho initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $23.00 price target on the stock. Finally, analysts at Needham & Company initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $14.00 price target on the stock.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 5.59% during mid-day trading on Friday, hitting $12.2799. The stock had a trading volume of 644,513 shares. BioCryst Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $12.35. The stock’s 50-day moving average is $10.13 and its 200-day moving average is $7.27. The company’s market cap is $725.6 million. BioCryst Pharmaceuticals also saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 5,356,831 shares, a decline of 31.4% from the January 15th total of 7,809,393 shares. Approximately 10.6% of the company’s shares are sold short. Based on an average trading volume of 1,550,929 shares, the days-to-cover ratio is currently 3.5 days.
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.